Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
0.7100
+0.0100 (1.43%)
Jul 25, 2025, 3:29 PM EDT
Vaccinex Employees
As of December 31, 2024, Vaccinex had 27 total employees, including 23 full-time and 4 part-time employees. The number of employees decreased by 13 or -32.50% compared to the previous year.
Employees
27
Change (1Y)
-13
Growth (1Y)
-32.50%
Revenue / Employee
$24,040
Profits / Employee
-$745,360
Market Cap
1.90M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27 | -13 | -32.50% |
Dec 31, 2023 | 40 | -3 | -6.98% |
Dec 31, 2022 | 43 | 2 | 4.88% |
Dec 31, 2021 | 41 | 1 | 2.50% |
Dec 31, 2020 | 40 | -9 | -18.37% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Vaccinex News
- 2 months ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 5 months ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 5 months ago - ARMISTICE CAPITAL, LLC Reduces Stake in Vaccinex Inc: A Strategic Portfolio Adjustment - GuruFocus
- 7 months ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 8 months ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 9 months ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire